Almirall has licensed an interleukin-2 (IL-2) drug from China's Simcere Pharma, joining the ranks of companies looking at blocking the cytokine as a way to treat autoimmune diseases.
Atopic dermatitis (AD) is a highly prevalent chronic dermatological disease, with symptoms which include itching, dry skin, severe pain, and inflammation – all of which create considerable
An alliance between Spanish drugmaker Almirall and digital health company Happify has yielded its first fruit, with the launch of their Claro app designed to reduce anxiety and improve well
There is a bright future ahead for open innovation in pharma, as Almirall executive vice-president, research and development chief scientific officer Karl Ziegelbauer explains.
South Korea’s Hyundai Bioscience is preparing to start clinical trials of what it hopes could become the first antiviral treatment for dengue fever, a mosquito-borne viral
It’s 2024, and in most clinical trials, data is still being moved from the EHR to the EDC manually – with employees reading data from one screen and typing it onto another.
